Cargando…

Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study

BACKGROUND: Postinjection delirium/sedation syndrome (PDSS) has been reported uncommonly during treatment with olanzapine long-acting injection (LAI), a sustained-release formulation of olanzapine. AIMS: The primary aim of the study was to estimate the incidence per injection and per patient of PDSS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyers, Kristin J., Upadhyaya, Himanshu P., Landry, John L., Chhabra-Khanna, Rashna, Falk, Deborah M., Seetharama Rao, Balasubramanya, Jones, Meghan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal College of Psychiatrists 2017
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550823/ https://www.ncbi.nlm.nih.gov/pubmed/28811926 http://dx.doi.org/10.1192/bjpo.bp.116.004382

Ejemplares similares

Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection
por: Sarangula, Sadhvi Mythili, et al.
Publicado: (2016)

Postinjection delirium/sedation syndrome with long-acting olanzapine pamoate in a middle-aged female
por: Upadhyay, Apoorva, et al.
Publicado: (2017)

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
por: Bushe, Chris J, et al.
Publicado: (2015)

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study
por: Jones, Meghan E., et al.
Publicado: (2015)

Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy
por: Gerving, Joshua, et al.
Publicado: (2022)

Is Low Body Mass Index a Risk Factor for Postinjection Delirium/Sedation Syndrome?
por: Punnoose, Zarine Maria, et al.
Publicado: (2017)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

Case series profile of olanzapine post‐injection delirium/sedation syndrome
por: Seebaluck, Jason, et al.
Publicado: (2022)

Postinjection Muscle Fibrosis from Lupron
por: Everest, Erica, et al.
Publicado: (2015)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium
por: Jain, Rajan, et al.
Publicado: (2017)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
por: Peuskens, Joseph, et al.
Publicado: (2012)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

Mask use by patients in the context of COVID‐19 can increase the risk of postinjection endophthalmitis
por: Blom, Kathrine, et al.
Publicado: (2021)

Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis
por: Van den Berghe, N., et al.
Publicado: (2019)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Additional sedative drugs to light sedation with dexmedetomidine is risk for delirium
por: Sakuraya, M, et al.
Publicado: (2015)

Levomepromazine: Delirium and sedation: case report
Publicado: (2021)

Delirium Associated with Olanzapine Therapy in an Elderly Male with Bipolar Affective Disorder
por: Sharma, Ravi C., et al.
Publicado: (2010)

Letter to editor regarding “comparison of efficacy of haloperidol and olanzapine in the treatment of delirium”
por: Kumar, Pawan, et al.
Publicado: (2019)

Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis
por: Liu, Si Bo, et al.
Publicado: (2023)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

IVIVC from Long Acting Olanzapine Microspheres
por: D'Souza, Susan, et al.
Publicado: (2014)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
por: Detke, Holland C., et al.
Publicado: (2014)

Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital
por: Grover, Sandeep, et al.
Publicado: (2020)

The effect of popliteal sciatic nerve block with methylprednisolone in the management of postinjection sciatic neuropathy after clinical and electrophysiological examination
por: YÜRÜK, Damla, et al.
Publicado: (2021)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Sedation, delirium and psychological distress: let's not be deluded
por: Griffiths, Richard D
Publicado: (2012)

The complex interplay between delirium, sepsis and sedation
por: Kress, John P
Publicado: (2010)

Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Clinical, electrophysiological, and prognostic study of postinjection sciatic nerve injury: An avoidable cause of loss of limb in the peripheral medical service
por: Maqbool, Wani, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_t7pduuciiaalr59qchjgpufrlb